In a cohort study involving 597 patients treated with primary treatment for gastric cancer, the OS with positive expression of LOXL1, LOXL3, or LOXL4 was significantly shorter than with negative LOXL4 expression. This evidence concerns the gene LOXL3 and gastric cancer.